

SEDATIVES AND HYPNOTICS



SEDATIVE:

Drug or dose of the drug that produce **calmness** of the mind **without inducing sleep**
→ Drowsiness/Sleepiness



HYPNOTIC:

Drug that induce &/or **maintains sleep** from which a person can be **aroused** as during natural sleep




SLEEP

- Transient physiological depression.
- Characterised- cyclical eye movements, muscular relaxation, EEG changes
- 2 categories : **NREM** and **REM** sleep.
- NREM further divided into 5 stages : Phases 0, 1, 2, 3, 4.




Stages of Sleep



NEUROTRANSMISSION

- Balance should be maintained between excitatory (glutamnergic) and inhibitory (GABAergic) transmissions.



SLEEP

NREM

80% of sleep
Slow wave sleep
BP,HR,RR decreased
Relaxed muscles
EEG : low frequency and high amplitude
For physical restoration

Somnambulism, Eneuresis,
Somnoloqui, Bruxism,
Pavor Nocturnus

REM

20% of sleep
Fast wave sleep
BP,HR,RR fluctuating
Profoundly relaxed muscles
For consolidation of learning

Active dreaming, Night Mares,
Narcolepsy, Cataplexy,
Penile erection

SEDATIVE-HYPNOTICS



PHARMACOLOGICAL THERAPY

- **Ideal hypnotic :**

- ✓ Induce and maintain sleep with normal architecture
- ✓ No rebound anxiety or sedation on next day
- ✓ No rebound insomnia on discontinuation
- ✓ No interaction with other drugs
- ✓ No dependency on chronic usage

Sedatives and hypnotics

Benzodiazepine.

Barbiturates

Non-benzodiazepines

Other hypnotics

Long acting

Intermediate acting

Short acting

Long acting

Intermediate acting

Short acting

- Diazepam
- Chlordiazepoxide
- Clonazepam
- Flurazepam

- Alprazolam
- Estazolam
- Lorazepam

- Triazolam
- Oxazepam
- Midazolam

- Phenobarbitone

- Butobarbitone
- Pentobarbitone

- Thiopentone
- Methohexitone

- Zopiclone
- Eszopiclone
- Zoleplon
- Zolpidem

- Triclofos
- Melatonin
- Ramelteon
- Suvorexant

Epilepsy
Neonatal jaundice

Anaesthesia

Benzodiazepines a/c to Indications

Hypnotic

- Diazepam
- Flurazepam
- Nitrazepam
- Alprazolam
- Temazepam
- Triazolam

Antianxiety

- Diazepam
- Chlordiazepoxide
- Oxazepam
- Lorazepam
- Alprazolam

Anticonvulsant

- Diazepam
- Lorazepam
- Clonazepam
- Clobazam

MOLECULAR PHARMACOLOGY OF GABA RECEPTOR




Fig.36.4 Model of side view of structure of GABA-A receptor (ligand gated ion channel) chloride channel complex (ionophore). The GABA-A receptor is comprised of 5 units (two α , two β & γ) arranged like a rosette surrounding the chloride channel which is in the centre & it has binding site (see cross sectional view) for GABA (α & β subunits), benzodiazepines (α & γ subunits), barbiturates (β subunit) and alcohol (α subunit). These substances/drugs after combining with their receptors/binding sites increase chloride conductance and thus facilitate GABAergic




Fig.36.5 Model of cross sectional view of structure of GABA-A receptor (ligand gated ion channel) chloride channel complex (ionophore) & binding site for GABA (α & β subunits), benzodiazepines (α & γ subunits), barbiturates (β subunit) and alcohol (α subunit)

GABA RECEPTOR

Mutation in $\alpha 1$ subunit




Resistance to sedative and amnestic effects without any effect on anxiolytic and muscle relaxant actions

Mutation in $\alpha 2$ subunit



Resistance in anxiolytic actions

DOSE RESPONSE CURVE




MECHANISM OF ACTION

BENZODIAZEPINES

- Facilitatory action
- Increase frequency of chloride channel opening

BARBITURATES

- Facilitatory action by increasing the duration of the chloride channel
- At higher doses, show GABA mimetic action, directly increase ion conductance



BARBITURATES

CLASSIFICATION

ULTRA SHORT ACTING

- THIOPENTAL , METHOHEXITAL

SHORT ACTING (3-8HRS)

- PENTOBARBITAL
- SECOBARBITAL
- AMOBARBITAL

INTERMEDIATE ACTING (8-24H)


- AMYLOBARBITONE

LONG ACTING (>24H)

- PHENOBARBITONE

MECHANISM OF ACTION

1. **GABA facilitatory action** : by prolonging the duration of chloride channel opening and at higher doses directly activate and increase influx of chloride.
 2. Decrease **glutamate-induced depolarization** (by inhibiting AMPA receptors).
 3. Inhibit voltage dependent **Na⁺ and K⁺ conductances**.
- Multiplicity of actions – surgical anaesthesia
profound CNS depression and
low margin of safety



PHARMACOKINETICS

- **Absorption** : - rapid oral absorption
- IM Injection : Necrosis

- **Distribution** : - wide distribution (high lipid solubility)
- redistribution into muscle and fat occurs- terminates the action
- readily crosses placenta

PHARMACOKINETICS

- **Metabolism** : - by liver microsomal enzymes
 - oxidation → conjugation → excreted in urine
 - oxidation at 5th carbon – terminates the action
 - 25% of phenobarbital and aprobarbital are excreted unchanged in urine
- **Excretion** : - ↑ t_{1/2} in elderly and cirrhotic patients
 - drug accumulation occurs on repeated administration
 - weak acids – **ALKALINIZATION** increases their excretion

PHARMACOLOGICAL ACTIONS

- Dose dependent action :



- Presence of even moderate pain – decreases sedative activity → **HYPERALGESIC** action.
- Higher doses :
 - suppress hypoxic and chemoreceptor drives → Respiratory depression.
 - cardiodepressant
 - circulatory collapse due to medullary vasomotor depression

PHARMACOLOGICAL ACTIONS

- **Hypnotic** :
 - ↑ total sleep time
 - ↓ sleep latency
 - ↓ REM sleep and Slow-wave sleep
 - number of awakenings
 - > 2 wks – tolerance
 - discontinuation : rebound increase of all parameters

- **Enzyme induction** :
 - potent enzyme inducer of CYP'S – drug interactions and tolerance.
 - induces ALA synthetase, exacerbations in Acute Intermittent Porphyria.

THERAPEUTIC USES

- **INSOMNIA** : amobarbital, butobarbital, pentobarbital, secobarbital.
- **PREOP-SEDATION** : amobarbital, butobarbital, pentobarbital, secobarbital, thiopental
- **INDUCTION OF ANAESTHESIA** : thiopental, methohexital
- **ANTICONVULSANT** : phenobarbital in status epilepticus
mephobarbital as second line anticonvulsant
- **HYPERBILIRUBINEMIA OF NEONATES** : due to increased activity of glucosyl transferase.

ADVERSE EFFECTS

- **TOLERANCE** : - mood, sedation, hypnosis >> anticonvulsant
- **DEPENDENCE AND ABUSE**
- **WITHDRAWAL SYMPTOMS**
- **HANGOVER**
- **DRUG AUTOMATISM**

ADVERSE EFFECTS :

- **HYPERSENSITIVITY**
- **VITAMIN K AND D METABOLISM** : increased by phenobarbital
 - impairs bone mineralization and coagulation defects in newborns.
- **UNWANTED PREGNANCY** : due to increased metabolism of OCP'S.

CONTRAINDICATIONS :

- Acute Intermittent Porphyria
- respiratory insufficiency
- liver diseases
- elderly
- pregnancy

BARBITURATE POISONING

- Suicidal >> Accidental - >> 10 times the hypnotic dose.
- With Alcohol or CNS depressants – occurs at low doses.
- Severe intoxication : - patient – comatose
 - respiration : shallow and rapid
 - cardiac depression and circulatory collapse
 - renal failure
- Treatment : - supportive measures
 - artificial respiration
 - gastric lavage
 - forced alkaline diuresis
 - hemodialysis if necessary


BENZODIAZEPINES

BENZODIAZEPINES - PHARMACOKINETICS

- Lipophilic
- Complete oral absorption except for CLORAZEPATE which is rapidly decarboxylated to N-desmethyldiazepam (Nordazepam) by gastric juice.
- Rapid distribution into brain followed by redistribution into muscle and fat.
- Metabolism : by CYP'S 3A4 and 2C19.
- Cross placenta and excreted in milk - fetal and neonatal depression.

PHARMACOLOGICAL ACTIONS

1. SEDATIVE AND HYPNOTIC :



2. ANXIOLYTIC : Mainly used for Acute Anxiety States.

3. PREANAESTHETIC MEDICATION : Eg: chlordiazepoxide, diazepam, lorazepam, midazolam.

PHARMACOLOGICAL ACTIONS

4. **ANTICONVULSANT** : diazepam , lorazepam – used in status epilepticus.

5. **ANTEROGRADE AMNESIA** : mediated by $\alpha 1$ subunit of GABA-A receptor.

6. **MUSCLE-RELAXANT** : at higher doses, mediated by $\alpha 2$ subunit of GABA-A receptor.

7. **RESPIRATORY** : higher doses- decreases hypoxic drive and depress alveolar ventilation, hence not used in COPD patients.

Even hypnotic doses decrease muscle tone of upper airway in Obs.Sleep Apnea patients.

THERPEUTIC USES

- **Longer t_{1/2} BZD'S** : anticonvulsants and anti-anxiety agents
- **Shorter t_{1/2} BZD'S** : sedative-hypnotics.
- **ANXIOLYTICS** : Acute Anxiety States

Alprazolam – panic disorders, and agoraphobia.

Diazepam, Lorazepam, Oxazepam.

- **INSOMNIA** : short acting agents more preferred.

eg : estazolam, triazolam, temazepam.

- **ALCOHOL WITHDRAWAL** : Chlordiazepoxide, Clorazepate, Diazepam, Oxazepam.

THERAPEUTIC USES

- **ANAESTHESIA** : Preanaesthetic medication to produce amnesia – diazepam, lorazepam
Both intraoperative and preanaesthetic medication – midazolam
- **STATUS EPILEPTICUS** : Diazepam, Lorazepam.
- **OTHER EPILEPSIES** : Clonazepam – Myoclonic Seizures.
Clonazepam – Complex Partial Seizures.
- **SKELETAL MUSCLE RELAXANT** : Diazepam in Spastic disorders.

ADVERSE EFFECTS

- **Common side effects** : headache, blurred vision, nausea ,vomiting.
- **Impaired cognition**
- **Residual day time sleepiness**
- **Tolerance**
- **Dependency and Abuse liability** : eg : Flunitrazepam (ROHYPNOL)
- **Withdrawal syndromes** : rebound insomnia, anxiety, tremors, unpleasant dreams, anorexia, dizziness.

BENZODIAZEPINES

- **Drug interactions** : seen with enzyme inhibitors (erythromycin, ketoconazole)
 - CIMITIDINE and OCP'S : inhibit dealkylation and hydroxylation of BZD'S.
 - ETHANOL – synergistic effect on CNS depression, hence should not be used along ethanol and other CNS depressants.
 - Neonatal depression and **HYPOTONIA (FLOPPY BABY SYNDROME)** when given in pregnant female.

- **Dose reduction** : Elderly

Liver disease



ADVANTAGES OF BENZODIAZEPINES

BARBITURATES

- Narrow therapeutic index
- More suppression of REM sleep
- Enzyme inducer
- High abuse liability
- Produces non-specific CNS depression
- No antidote available

BENZODIAZEPINES

- High therapeutic index
- Less suppression of REM sleep
- Not an enzyme inducer
- Lesser abuse liability
- Do not produce
- Antidote – **Flumazenil** available